The 36-month beta value for GNPX is also noteworthy at -0.70. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for GNPX is 2.43M, and at present, short sellers hold a 3.51% of that float. The average trading volume of GNPX on October 25, 2024 was 8.36M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
GNPX) stock’s latest price update
Genprex Inc (NASDAQ: GNPX) has experienced a rise in its stock price by 2.10 compared to its previous closing price of 2.14. However, the company has seen a gain of 429.06% in its stock price over the last five trading days. prnewswire.com reported 2024-10-24 that Research to Study TUSC2 Combined with ALK-Inhibitors Collaboration with Non-Profit Patient-Focused Research Group Expands Potential Lung Cancer Patient Population for Reqorsa® Gene Therapy AUSTIN, Texas , Oct. 24, 2024 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company has entered into a Sponsored Research Agreement (SRA) with the University of Michigan Rogel Cancer Center to study TUSC2, the tumor suppressor gene used in Genprex’s lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), in combination with ALK-inhibitors in ALK-EML4 positive translocated lung cancer. The Company also announced its collaboration with ALK Positive, a non-profit patient-driven research organization dedicated to improving the life expectancy and quality of life for ALK-positive (ALK+) lung cancer patients.
GNPX’s Market Performance
Genprex Inc (GNPX) has seen a 429.06% rise in stock performance for the week, with a 525.18% gain in the past month and a 21.39% surge in the past quarter. The volatility ratio for the week is 90.25%, and the volatility levels for the past 30 days are at 29.12% for GNPX. The simple moving average for the past 20 days is 152.67% for GNPX’s stock, with a -19.31% simple moving average for the past 200 days.
Analysts’ Opinion of GNPX
Many brokerage firms have already submitted their reports for GNPX stocks, with National Securities repeating the rating for GNPX by listing it as a “Buy.” The predicted price for GNPX in the upcoming period, according to National Securities is $7 based on the research report published on January 26, 2021 of the previous year 2021.
Noble Capital Markets, on the other hand, stated in their research note that they expect to see GNPX reach a price target of $5. The rating they have provided for GNPX stocks is “Outperform” according to the report published on April 29th, 2019.
GNPX Trading at 231.08% from the 50-Day Moving Average
After a stumble in the market that brought GNPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.23% of loss for the given period.
Volatility was left at 29.12%, however, over the last 30 days, the volatility rate increased by 90.25%, as shares surge +519.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +252.81% upper at present.
During the last 5 trading sessions, GNPX rose by +456.90%, which changed the moving average for the period of 200-days by -73.88% in comparison to the 20-day moving average, which settled at $0.87. In addition, Genprex Inc saw -76.25% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GNPX
Current profitability levels for the company are sitting at:
- -1135.36 for the present operating margin
- 0.48 for the gross margin
The net margin for Genprex Inc stands at -1129.06. The total capital return value is set at -6.05. Equity return is now at value -318.88, with -232.21 for asset returns.
Currently, EBITDA for the company is -31.06 million with net debt to EBITDA at 0.09. When we switch over and look at the enterprise to sales, we see a ratio of 139.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.95.
Conclusion
In summary, Genprex Inc (GNPX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
